The Vision business at Johnson & Johnson MedTech has hit its latest milestone, earning a significant regulatory nod for its ...

Please provide your email address to receive an email when new articles are posted on . A new accommodating IOL improved visual function, accommodation and contrast sensitivity, according to a study.

Please provide your email address to receive an email when new articles are posted on . “Contrast sensitivity is also degraded by MFIOLs, and it was not known whether patients with MFIOL pseudophakia ...

JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...

Impaired vision and blindness are common. About 3.4 million people in the US are blind or visually impaired. Vision is usually measured by visual acuity charts, and normal vision is expressed as 20/20 ...

TECNIS PureSee IOL197% of patients would recommend this IOL to friends or family2TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...

FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...

Enhanced monofocal IOLs may improve intermediate vision and preserve visual function in glaucoma patients. The study showed significant improvements in BCVA, RNFLT, and IOP for both enhanced and ...